Tag Archives: Dr. Bimal Shah

September, 2015

  • 9 September

    Biosimilars’ Success in the US: Will Physicians Rule the Road?

    By Kathleen P. Wolff, MBA Specialty Pharma Journal As the high cost of new biologic medicines sends U.S. healthcare costs soaring, payers are anxiously anticipating the introduction of biosimilar medicines – biological products, approved by FDA because they are highly similar to an already FDA-approved biological product. However, there is one …